anti-CD33 CAR T-cell therapy (CRISPR Therapeutics)

N/A

Report date: 2025/03/14 16:31:43

Base Information

Drug Nameanti-CD33 CAR T-cell therapy (CRISPR Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesCrispr Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A